Kopel Hagit, Araujo Andre B, Bogdanov Alina, Zeng Ni, Winer Isabelle, Winer-Jones Jessamine P, Lu Tianyi, Marks Morgan A, Bonafede Machaon, Nguyen Van Hung, Martin David, Mansi James A
Medical Affairs, Moderna, Inc., Cambridge, Massachusetts, USA.
Real World Evidence, Veradigm, Chicago, Illinois, USA.
Open Forum Infect Dis. 2024 Nov 26;11(12):ofae695. doi: 10.1093/ofid/ofae695. eCollection 2024 Dec.
This study aimed to evaluate the vaccine effectiveness (VE) of mRNA-1273.815, a 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine, at preventing COVID-19-related hospitalizations and any medically attended COVID-19 in adults.
In a linked electronic health record-claims dataset, we identified US adults (≥18 years) who received the mRNA-1273.815 vaccine (exposed cohort) between 12 September and 15 December 2023, matched 1:1 to individuals who did not receive a 2023-2024 updated COVID-19 vaccine (unexposed cohort). Cohorts were balanced using inverse probability of treatment weighting on demographics, vaccination and infection history, and underlying medical conditions. Study cohorts were followed until 31 December 2023 for COVID-19-related hospitalizations and medically attended COVID-19. Cox regression was used to estimate hazard ratios and VE. Subgroup analyses were performed for adults ≥50 years, adults ≥65 years, and individuals with underlying medical conditions.
Overall, 859 335 matched pairs of mRNA-1273.815 recipients and unexposed adults were identified. The mean (standard deviation) age was 63 (16) years. More than 60% of individuals in both cohorts had an underlying medical condition. Among the overall adult population, VE was 60.2% (95% confidence interval, 53.4-66.0) against COVID-19-related hospitalization and 33.1% (30.2-35.9) against medically attended COVID-19 over a median follow-up of 63 (interquartile range: 44-78) days. VE estimates by age and underlying medical conditions were similar.
These results demonstrate the significant protection provided by mRNA-1273.815 against COVID-19-related hospitalizations and any medically attended COVID-19 in adults, regardless of vaccination history, and support Centers for Disease Control and Prevention recommendations to stay up-to-date with COVID-19 vaccination to prevent COVID-19-related outcomes, including hospitalizations.
本研究旨在评估2023 - 2024年含奥密克戎XBB.1.5的mRNA新冠疫苗mRNA-1273.815在预防成人新冠病毒病(COVID-19)相关住院和任何接受医疗护理的COVID-19方面的疫苗效力(VE)。
在一个关联的电子健康记录-理赔数据集里,我们识别出2023年9月12日至12月15日期间接种了mRNA-1273.815疫苗的美国成年人(≥18岁)(暴露队列),并将其与未接种2023 - 2024年更新新冠疫苗的个体(未暴露队列)进行1:1匹配。通过对人口统计学、疫苗接种和感染史以及基础疾病状况进行治疗权重的逆概率加权,使队列达到平衡。研究队列随访至2023年12月31日,观察与COVID-19相关的住院情况和接受医疗护理的COVID-19情况。采用Cox回归来估计风险比和VE。对年龄≥50岁的成年人、年龄≥65岁的成年人以及有基础疾病的个体进行亚组分析。
总体上,共识别出859335对匹配的mRNA-1273.815接种者和未暴露成年人。平均(标准差)年龄为63(16)岁。两个队列中超过60%的个体有基础疾病。在全体成年人群中,在中位随访63天(四分位间距:44 - 78天)期间,针对COVID-19相关住院的VE为60.2%(95%置信区间,53.4 - 66.0),针对接受医疗护理的COVID-19的VE为33.1%(30.2 - 35.9)。按年龄和基础疾病状况估计的VE相似。
这些结果表明,mRNA-1273.815在预防成人COVID-19相关住院和任何接受医疗护理的COVID-方面提供了显著保护,无论疫苗接种史如何,并支持疾病控制与预防中心关于及时接种COVID-19疫苗以预防包括住院在内的COVID-19相关结局的建议。